Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | ADH4 | P08319 | 1/20 | 0.43 |
| ▸ | ADH7 | P40394 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
| ▸ | FDPS | P14324 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14911157 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL9181091 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL38656174 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL31207037 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL402299 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL23945469 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL9207279 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL18169171 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL130471 | 0.97 | OPRM1 (0.52) | OPRM1TSHRTHRBSPHK1LMNA | |
| SCHEMBL671923 | 0.89 | OPRM1 (0.46) | OPRM1TSHRTHRBSPHK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140888-A1 | COMPOSITION COMPRISING AN ALKANE AND AN OXOESTER | BIOSYNTHIS (FR) | 2024-05-02 | — | — | US | claimed |
| CN-108034512-A | A kind of Multi-function dry washing material and preparation method thereof | 东莞智高化学科技有限公司 | 2018-05-15 | — | — | CN | claimed |
| WO-2013173332-A1 | METHOD FOR SELECTIVE PRODUCTION OF BIOBASED CHEMICALS AND BIOFUELS FROM PLANT LIGNIN | Vertichem Corporation (CA) | 2013-11-21 | — | — | WO | claimed |
| US-20130232852-A1 | METHOD FOR TIERED PRODUCTION OF BIOBASED CHEMICALS AND BIOFUELS FROM LIGNIN | THESIS CHEMISTRY, LLC (US) | 2013-09-12 | — | — | US | claimed |
| US-20130232853-A1 | METHOD FOR SELECTIVE PRODUCTION OF BIOBASED CHEMICALS AND BIOFUELS FROM PLANT LIGNIN | THESIS CHEMISTRY, LLC (US) | 2013-09-12 | — | — | US | claimed |
| WO-2013134756-A1 | A METHOD FOR TIERED PRODUCTION OF BIOBASED CHEMICALS AND BIOFUELS FROM LIGNIN | Vertichem Corporation (CA) | 2013-09-12 | — | — | WO | claimed |
| US-20250197341-A1 | METHOD FOR INHIBITING CRYSTALLISATION | BIOSYNTHIS (FR) | 2025-06-19 | — | — | US | disclosed |
| WO-2024141382-A1 | METHOD FOR PRODUCING ISOXAZOLINECARBOXYLIC ACID DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-07-04 | — | — | WO | disclosed |
| EP-3668845-B1 | HERBICIDALLY ACTIVE 3-PHENYL-5-TRIFLUORMETHYLISOXAZOLIN-5-CARBOXAMIDES OF CYCLOPENTYL CARBOXYLIC ACIDS AND ESTERS | BAYER AG (DE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4378314-A2 | HERBICIDAL COMPOSITIONS | Bayer AG (DE) | 2024-06-05 | — | — | EP | disclosed |
| EP-4373277-A1 | METHOD FOR SPOT-TREATMENT APPLICATION AGAINST WEEDS | Bayer Aktiengesellschaft (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20240140888-A1 | COMPOSITION COMPRISING AN ALKANE AND AN OXOESTER | BIOSYNTHIS (FR) | 2024-05-02 | — | — | US | disclosed |
| EP-4358718-A1 | (1,4,5-TRISUBSTITUTED-1H-PYRAZOLE-3-YL)OXY-2-ALKOXY ALKYL ACIDS AND THEIR DERIVATIVES, THEIR SALTS AND THEIR USE AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2024-05-01 | — | — | EP | disclosed |
| US-5356907-A | 1-cycloalkylpyridones as analgesics | ROUSSEL UCLAF (FR) | 1994-10-18 | — | — | US | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
| US-4524230-A | Preparation of alkylaromatic compounds | UOP INC. (US) | 1985-06-18 | — | — | US | disclosed |
| US-4524024-A | INCLUDING A HYDROLYSIS OF ESTERS TO INCREASE YIELD; DISTILLATION | THE BADGER COMPANY, INC. (US) | 1985-06-18 | — | — | US | disclosed |
| US-3992451-A | IN THE PRESENCE OF FREE RADICAL CATALYSTS, HYDROGEN CHLORIDE, AND CARBON MONOXIDE | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3962448-A | CNS DEPRESSANTS, VETERINARY | SMITHKLINE CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140888-A1 | COMPOSITION COMPRISING AN ALKANE AND AN OXOESTER | ALKBH2, ABHD12, FAAH2 | OPRM1 855/4885TSHR 3034/4885THRB 3627/4885 |
| US-20130232852-A1 | METHOD FOR TIERED PRODUCTION OF BIOBASED CHEMICALS AND BIOFUELS FROM LIGNIN | DCXR, AGL, GLO1 | OPRM1 4092/4885TSHR 4782/4885THRB 4127/4885 |
| US-20130232853-A1 | METHOD FOR SELECTIVE PRODUCTION OF BIOBASED CHEMICALS AND BIOFUELS FROM PLANT LIGNIN | HAAO, HAO2, HACL2 | OPRM1 3280/4885TSHR 4699/4885THRB 4021/4885 |
| US-20250197341-A1 | METHOD FOR INHIBITING CRYSTALLISATION | FASN, SCD5, NFKB2 | OPRM1 4200/4885TSHR 3901/4885THRB 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.